

MISONIX INC  
Form 8-K  
March 07, 2017

**UNITED STATES**

**SECURITIES AND EXCHANGE COMMISSION**

**Washington, DC 20549**

**FORM 8-K**

**CURRENT REPORT**

**Pursuant to Section 13 or 15(d)**

**of the Securities Exchange Act of 1934**

Date of Report (Date of earliest event reported): **March 7, 2017**

**MISONIX, INC.**

(Exact name of Registrant as specified in its charter)

**11-2148932**

**New York**

**1-10986**

(I.R.S. Employer

(State or other jurisdiction

(Commission File Number) Identification No.)

of incorporation)

**1938 New  
Highway,  
Farmingdale,  
New York  
11735**

(Address of  
principal  
executive  
offices,  
including zip  
code)

**(631)  
694-9555**

(Registrant's  
telephone  
number,  
including area  
code)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (*see* General Instruction A.2. below):

Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

**Item 8.01. Other Events**

On March 7, 2017, Misonix, Inc. (the “Company”) issued the press release attached hereto as Exhibit 99.1 announcing the appointment of Shandong Weigao Orthopedic Device Company Limited, a subsidiary of Shandong Weigao Group Medical Polymer Company Limited, as the exclusive distributor of the Company’s BoneScalpel product line in the People’s Republic of China, Hong Kong and Macao.

**Item 9.01. Financial Statements and Exhibits**

(d) *Exhibits*

**Exhibit No. Description of Exhibit**

99.1 Press Release dated March 7, 2017

**SIGNATURES**

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

MISONIX, INC.

Date: March 7, 2017 By: /s/Stavros G. Vizirgianakis  
Stavros G. Vizirgianakis  
Chief Executive Officer